Our Latest Thinking on Some of the Industry’s Hottest Topics

Schedule Crashers

How to identify and mitigate risks to keep your timeline on track. Biopharma companies can be an optimistic bunch – at least at the beginning of a project. When they find a molecule that shows promise, they are eager to get it to market as quickly as possible – and...

read more

Sound Clinical Strategies: Wwwwwh?

How asking the right questions during clinical development planning can prevent costly mistakes down the line.   When a biopharma company, and its investors, get excited about a new molecule, it can be easy to dive straight into clinical development. The sooner...

read more

Kidney Week 2017 Examines the Future of Personalized Nephrology

Next week, I’ll be heading to New Orleans to join 13,000 other kidney professionals at the American Society of Nephrology’s Kidney Week 2017. This is a priority therapeutic area for Clinipace Worldwide. Held from October 31 to November 5, the ASN meeting’s theme is...

read more

Brexit – Enormous Impact to Pharma Operating in the UK and EU

Almost a year ago in June of 2016, the people of the UK voted to leave the European Union (Brexit).  This month it was announced that the negotiation between the EU and the UK to implement the Brexit would pause and continue in December of this year.  Although it has...

read more

Clinipace Expert Discusses Benefit of Standardized Data

The benefits of standardized data are well known — it improves communication; it makes better use of time and resources; it facilitates comparison; it adds transparency; it enhances data sharing and collaborators among scientists, studies and companies; and it eases...

read more

EU Data Privacy in 2017: What You Need to Know

Webcast presentation on Thursday, April 6th, 2017 @ 11:30am ET In 2016, the European Union (EU) approved new harmonized privacy regulations, known as the General Data Protection Regulations (GDPR). The GDPR will impose greater obligations on companies established in...

read more

Visit Clinipace at the DGPharMed 33rd Annual Congress

The Clinipace Worldwide team from Germany is looking forward to connecting with friends and colleagues at the upcoming 33rd Annual DGPharMed Conference/Congress in Berlin. The event, coming up this week from March 23rd – 24th is titled, “Drug and product development tomorrow: Striking new paths?”

read more

Clinipace Exhibits @ Partnerships in Clinical Trials

Will you be attending Partnerships in Clinical Trials in Vienna on November 16th and 17th? The theme for the event is “Accelerate Clinical Development and Improve Trial Quality by Benchmarking and Enhancing Clinical Practices and Partnering,” and who knows how to accelerate clinical development and improve trial quality, better than a digital CRO?

read more

Clinipace Stats Experts Answer Questions at PhUSE 2016

Our team at Clinipace Worldwide is looking forward to exhibiting at the upcoming PhUSE 2016 conference in Barcelona. The focus of this year’s conference will be around how to standardize and design trials and utilize data more effectively to reduce the time to...

read more

Clinipace Team Talks Innovation in Cancer Therapy at ASCO 2016

Last week, we spent time with some of the best and brightest minds in oncology at ASCO 2016 in Chicago. Speaking with so many professionals who are passionately advancing new therapies is a privilege and motivates our team to work even harder with our sponsors to develop the new treatments that are significantly improving the outcomes for patients.

read more

Understanding FDA’s Final Guidance on Exempt Infant Formula Production

Marci Ardinger is the Associate Director of Project Management at Clinipace Worldwide. Infant formulas play an important role in the overall health of infants that consume them, and the FDA has recognized that infant formulas for specific uses (i.e., infants with inborn errors of metabolism, low birth weight and other medical or dietary issues) might need

read more